title: Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
abstract: Computer-guided drug design is a powerful tool for drug discovery. Herein we disclose the use of this approach for the discovery of dual FMS-like receptor tyrosine kinase-3 (FLT3)-Aurora A inhibitors against cancer. An Aurora hit compound was selected as a starting point, from which 288 virtual molecules were screened. Subsequently, some of these were synthesized and evaluated for their capacity to inhibit FLT3 and Aurora kinase A. To further enhance FLT3 inhibition, structure-activity relationship studies of the lead compound were conducted through a simplification strategy and bioisosteric replacement, followed by the use of computer-guided drug design to prioritize molecules bearing a variety of different terminal groups in terms of favorable binding energy. Selected compounds were then synthesized, and their bioactivity was evaluated. Of these, one novel inhibitor was found to exhibit excellent inhibition of FLT3 and Aurora kinase A and exert a dramatic antiproliferative effect on MOLM-13 and MV4-11 cells, with an IC50 value of 7 nM. Accordingly, it is considered a highly promising candidate for further development.
authors.affiliation: Institute of Biotechnology & Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan (ROC).
authors.forename: Yung
authors.initials: Y
authors.lastname: Chang Hsu
authors.forename: Yi-Yu
authors.initials: YY
authors.lastname: Ke
authors.forename: Hui-Yi
authors.initials: HY
authors.lastname: Shiao
authors.forename: Chieh-Chien
authors.initials: CC
authors.lastname: Lee
authors.forename: Wen-Hsing
authors.initials: WH
authors.lastname: Lin
authors.forename: Chun-Hwa
authors.initials: CH
authors.lastname: Chen
authors.forename: Kuei-Jung
authors.initials: KJ
authors.lastname: Yen
authors.forename: John T-A
authors.initials: JT
authors.lastname: Hsu
authors.forename: Chungming
authors.initials: C
authors.lastname: Chang
authors.forename: Hsing-Pang
authors.initials: HP
authors.lastname: Hsieh
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D064096:Aurora Kinase A / Q000037:antagonists & inhibitors* / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D017076:Computer-Aided Design; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; C576917:AURKA protein, human; D064096:Aurora Kinase A
keywords: Aurora kinase A; FLT3; drug design; inhibitors; leukemia